QuantLogix's current estimate for PathAI, published 2026-11-12 — below the last disclosed round of $1.0B (2021-Q2).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$1.0B
2021-Q2
weight 0.02
Secondary market print
$756.84M
2026-06-27
weight 0.44
How this price has held up
No round has priced for PathAI since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-11-12 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, PathAI, 2026-11-12 (7eeb56dfa50b7288).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is PathAI going public?
No. PathAI is private and has not filed to go public. There is no S-1 on file.
What is PathAI's valuation in 2026?
PathAI is valued at $1.0B as of 2021-Q2, set by its Series C ($165M, May 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has PathAI filed an S-1?
No public S-1 is on file for PathAI.
How much has PathAI raised?
PathAI has raised $255M in total, most recently a Series C of $165M in May 2021.
Is PathAI publicly traded — can you buy PathAI stock?
No. PathAI is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for PathAI on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2016
HQ
Boston, MA
Employees
268
Total Raised
$255M
Last Round
Series C — $165M (May 2021)
IPO Status
private
Fundraising Status
Series C · $165M · 5y 6mo ago
privateTotal raised $255M
Secondary Market
Implied price / share
$21.89
Last round price / share
$29.5
vs last round
-25.8%
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$165M
May 2021
—
$1.0B
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for PathAI — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-11-12. Re-checked weekly.
Talent Signal
Hiring trend
▲ Hiring uptrend
+67% vs 2026-09
Open roles
15
via greenhouse
Product-build share
93%
engineering, research, product, design
Trajectory
expanding
heavy product build — 93% of open roles are product-building functions (engineering/research/product) — 7 of 15 open roles are engineering.
No tracked executive churn; open roles trending up.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Associate Director, MLOps EngineeringClinical Trial AssociateImplementation Engineer, Digital Diagnostics (DDx)Machine Learning Engineer II (Applied Research & Model Development)Machine Learning Engineer III (Applied Research & Model Development)Senior Program Manager
Counted from PathAI's live job board as of 2026-10-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Health CareBiotechnologyHealth Diagnostics
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q2. Refreshed quarterly.